Radioimmunoassay for the Synthetic Ergoline Derivative Cabergoline in Biological Fluids

References

• Jori , C. 1987 . Cabergoline: a new derivative with long lasting dopaminergic properties . Ital. J. Neurol. Sci. , 5 : 61 (suppl. 7)
   Google Scholar
• Pontiroli , A. , Viberti , G. , Mangili , R. , Cammelli , L. and Dubini , A. 1987 . Selective and extremely long inibition of prolactin release in man by 1-ethyl-3-(3′-dimethyl aminopropyl) -3-(6′-allylergoline-8′-beta-carbonyl) -urea -diphosphate (FCE 21336) . Br. J. Clin. Pharmacol. , 23 ( 4 ) : 433 – 8 .
   PubMed Web of Science ®Google Scholar
• Pianezzola , E. 1989 . Urine excretion rate and prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patient . Eur. J. Clin. Pharmacol. , 36 : A313 (suppl.)
   Google Scholar
• Jori , C. and Dubini , A. 1990 . Cabergoline in Parkinson's disease: a confirmation of the role of a long-lasting dopaminergic stimulation in motor fluctuations . J. Movement Disorders. , 5 : 62 (Suppl. 1)
   Google Scholar
• Taunton-Rigby , A. , Sher , S. and Kelley , P. 1973 . Lysergic acid diethylamide: radioimmunoassay . Science , 181 : 165 – 6 .
   PubMed Web of Science ®Google Scholar
• Mantegani , S. , Brambilla , E. , Ermoli , A. , Fontana , E. , Angiuli , P. and Vicario , G. P. 1991 . Synthesis of tritium and carbon-14 labelled N-[3-(dimethylamino)propy1]-N–(ethylamino) carbony1–6- (2-propeny1) ergoline-β-carboxamide (cabergoline), a potent long lasting prolacting lowering agent . J. Labelled Compd. Radiopharm. , 29 ( 5 ) : 519 – 33 .
   Web of Science ®Google Scholar
• Cocchiara , G. and Strolin Benedetti , M. Excretion, balance and metabolic pattern of 3H-cabergoline in man. Rev. Drug Metab . Drug Interact. , (in press)
   Google Scholar
• Pianezzola , E. , Bizollon , C. A. , Harte , C. and Strolin Benedetti , M. April 25–7 1990 . “ Setting up of a RIA for the determination of cabergoline in biological fluids: preliminary results ” . April 25–7 , VIII Colloque International de Radioimmunologie de Lyon .
   Google Scholar
• Cedarbaum , J. M. 1987 . Clinical pharmacokinetics of anti-parkinsonian drugs . Clin. Pharmacokinet. , 13 : 141 – 78 .
   PubMed Web of Science ®Google Scholar
• Hümpel , M. , Nieuweboer , B. , Hasan , S. H. and Wendt , H. 1981 . Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level . Eur. J. Clin. Pharmacol. , 20 : 47 – 51 .
   PubMed Web of Science ®Google Scholar
• Krause , W. , Dorow , R. , Nieuweboer , B. and Hasan , S. H. 1984 . Pharmacokinetics and Pharmacodynamics of the ergot derivative, transdihydrolisuride in man . Eur. J. Clin. Pharmacol. , 27 : 335 – 9 .
   PubMedGoogle Scholar